Abstract
Background: Accumulating evidence indicating more aggressive features of breast carcinoma (BC) in young women than their older counterparts have raised the question of whether these differences are present at the genetic level.
Methods: For this purpose, we performed a comparative analysis of the frequency of deletions of BRCA1, BRCA2, BRCAX, TP53, ATM, and RB1 and amplification of Cyclin D1 and also studied the interrelation and prognostic significance of these genetic alterations in 30 early onset (≤40 years) and 33 late onset (>40 years) cases of BC. These gene alterations were also studied in 11 other types of breast lesions.
Results: A differential pattern of alterations (deletion/amplification) was observed in the two age groups, with the sequence in younger women being BRCA1 (72%), TP53 (71%), ATM (64%), BRCA2 (62%), RB1 (60%), Cyclin D1 (43%), and BRCAX (24%) and that in the older group being TP53 (66%), RB1 (63%), BRCA1 (56%), ATM (53%), BRCA2 (45%), Cyclin D1 (24%), and BRCAX (23%). Similar, differential correlations were also seen with several clinicopathological parameters, prognosis, and combinations of alterations among these genes in the two age groups.
Conclusions: Differential frequencies and interrelationships of genetic alterations and prognoses in these two age groups indicate that the molecular pathways for the development of tumors in both age groups may not be similar, though the ultimate effect is deregulation of cell cycle checkpoints and defects in the DNA repair pathway.
Similar content being viewed by others
REFERENCES
Ferlay J, Bray F, Pisane P, Parkin DM. Cancer Incidence, Mortality and Prevalence Worldwide. Globocon 2000 (CD-ROM). IARC Press, 2001.
Wenger CR, Beardslee S, Owens MA, et al. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 1993; 28:9–20.
Bonnier P, Romain S, Charpin C, et al. Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. Int J Cancer 1995; 62:138–44.
Chunder N, Mandal S, Basu D, Roy A, Roychoudhury S, Panda CK. Deletion mapping of chromosome 1 in early onset and late onset breast tumors- a comparative study in eastern India. Pathol Res Pract 2003; 199:313–21.
Chung M, Chang HR, Bland KI, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 1996; 77:97–103.
Gentile M, Olsen K, Dufmats M, Wingren S. Frequent allelic losses at 11q24.1-q25 in young women with breast cancer: association with poor survival. Br J Cancer 1999a; 80:843–9.
Gentile M, Jungestrom MB, Olsen KE, Soderkvist P, Wingren S. P53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation. Eur J Cancer 1999b; 35:1202–7.
Naidu R, Wahab NA, Yadav MM, Kutty MK. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters. Oncol Rep 2002; 9:409–16.
Querzoli P, Albonico G, di Iasio MG, et al. Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women. Breast Cancer Res Treat 2001; 66:135–42.
Johnson SM, Shaw JA, Walker RA. Sporadic breast cancer in young women: prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2. Int J Cancer 2002; 98:205–9.
Nathanson KN, Wooster R, Weber BL. Breast cancer genetics: What we know and what we need. Nature Med 2001; 7:552–6.
Polyak K. Breast cancer gene discovery. Exp Rev Mol Med 15 August, 2002; http://www.expertreviews.org/0200491Xh.htm.
Hedenfalk I, Ringner M, Ben-Dor A, et al. Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci U S A 2003; 100:2532–7.
Kainu T, Juo SH, Desper R, et al. Somatic deletions in hereditary breast cancers implicate 13q21as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci U S A 2000; 97:9603–8.
Thompson D, Szabo CI, Mangion J, et al. Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci U S A 2002; 99:827–31.
Du Q, Lou L, von Wachenfeldt A, Kockum I, Luthman H, Lindblom A. No evidence for a familial breast cancer susceptibility gene at chromosome 13q21 in Swedish breast cancer families. Int J Cancer 2002; 98:799–800.
Xu B, Kim ST, Kastan MB. Involvement of Brca1 in S-phase and G2- phase checkpoints after ionizing radiation. Mol Cell Biol 2001; 21:3445–50.
Bartek J, Lukas J. Mammalian G1- and S-phase checkpoints in response to DNA damage. Curr Opinion Cell Biol 2001; 13:738–47.
Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 2001; 10:705–13.
Welcsh PL, Owens KN, King MC. Insights into the functions of BRCA1 and BRCA2. Trends Genet 2000; 16:69–74.
Zhang IL, Somasundaram K, Peng Y, Tian IL, Bi D, Weber BL, El-Diery WS. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 1998; 16:1713–21.
Wang A, Schneider- Broussard R, Kumar AP, MacLeod MC, Johnson DG. Regulation of BRCA1 by the Rb-E2F pathway. J Biol Chem 2000; 275:4532–6.
Welcsh P, Lee MK, Gonzalez-Hernandez RM, et al. BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci U S A 2002; 99:7560–5.
Schwab M, Claas A, Savelyeva L. BRCA2: a genetic risk factor for breast cancer. Cancer Lett 2002; 175:1–8.
Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early onset breast cancer. J Natl Cancer Inst 1999; 91:943–9.
Malone KE, Daling JR, Neal C, et al. Frequency of BRCA1/BRCA2 mutations in a population based sample of young breast carcinoma cases. Cancer 2000; 88:1393–402.
Yoshikawa K, Honda K, Inamoto T, et al. Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. Clin Cancer Res 1999; 6:1249–61.
Kerangueven F, Eisinger F, Noguchi T, et al. Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions. Oncogene 1997; 14:339–47.
Phelan CM, Borg A, Cuny M, et al. Consortium study on 1280 breast carcinomas: Allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. Cancer Res 1998; 58:1004–12.
Pestonjamasp PH, Mittra I. Analysis of BRCA1 involvement in breast cancer in Indian women. J Biosc 2000; 25:19–23.
Tong D, Kucera E, Schuster E, et al. Loss of heterozygosity (LOH) at p53 is correlated with LOH at BRCA1 and BRCA2 in various human malignant tumors. Int J Cancer 2000; 88:319–22.
Hanby AM, Kelsell DP, Potts HW, Gillett CE, Bishop DT, Spurr NK, Barnes DM. Association between loss of heterozygosity of BRCA1 and BRCA2 and morphological attributes of sporadic breast cancer. Int J Cancer 2000; 88:204–8.
Hamann U, Herbold C, Costa S, et al. Allelic imbalance on chromosome 13q: Evidence for involvement of BRCA2 and RB1 in sporadic breast cancer. Cancer Res 1996; 56:1988–90.
Eiriksdottir G, Johannesdottir G, Ingvarsson S, et al. Mapping of loss of heterozygosity at chromosome 13q: Loss at 13q12-q13 is associated with breast tumor progression and poor prognosis. Eur J Cancer 1998a; 34:2076–81.
Kwiatkowska E, Teresiak M, Breborowicz D, Mackiewicz A. Somatic mutations in the BRCA2 gene and high frequency of allelic loss of BRCA2 in sporadic male breast cancer. Int J Cancer 2002; 98:943–5.
Eiriksdottir G, Barkardottir RB, Agnarsson BA, et al. High incidence of loss of heterozygosity at 17p13 in breast tumours from BRCA2 mutation carriers. Oncogene 1998b; 16:21–6.
Seitz S, Poppe K, Fischer J, et al. Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters. J Pathol 2001; 194:318–26.
Laake K, Odegard A, Andersen TI, et al. Loss of heterozygosity at 11q23.1 in breast carcinomas: indication for involvement of a gene distal and close to ATM. Genes Chromosomes Cancer 1997; 18:175–80.
Laake K, Launonen V, Niederacher D, et al. Loss of heterozygosity at 11q23.1 and survival in breast cancer: results of a large European study. Genes Chromosomes Cancer 1999; 25:212–21.
Chano T, Kontani K, Teramoto K, Okabe H, Ikegawa S. Truncating mutations of RB1CC1 in human breast cancer. Nat Genet 2002; 31:285–8.
Vaziri SAJ, Tubbs RR, Darlington G, Casey G. Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers. Mol Pathol 2001; 54:259–63.
Harmer MH. UICC TNM Classification of Malignant Tumors. 3rd ed. Geneva: UICC, 1978:47–54.
Pandey M, Singh SP, Behere PB, et al. Quality of life in patients with early and advanced carcinoma of the breast. Eur J Surg Oncol 2000; 26:20–4.
Sambrook J, Fristch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
Ottini L, Masala G, D’Amico C, et al. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population based study in Italy. Cancer Res 2003; 63:342–7.
Regitnit P, Moser R, Thalhammer M, et al. Microsatellite analysis of breast carcinoma and corresponding local recurrences. J Pathol 2002; 198:190–7.
Simpson DJ, Magnay J, Bicknell JE, et al. Chromosome 13q deletion mapping in pituitary tumors: infrequent loss of the retinoblastoma susceptibility gene (RB1) locus despite loss of RB1 protein product in somatotrophinomas. Cancer Res 1999; 59:1562–6.
Melamed J, Einhorn JM, Ittamann MM. Allelic loss on chromosome 13q in human prostate carcinoma. Clin Cancer Res 1997; 3:1867–72.
MacGrogan D, Levy A, Bostwick D, Wagner M, Wells D, Bookstein R. Loss of chromosome arm 8p loci in prostate cancer: Mapping by quantitative allelic imbalance. Genes Chromosomes Cancer 1994; 10:151–9.
Dasgupta S, Mukherjee N, Roy S, et al. Mapping of candidate tumor suppressor genes’ loci on human chromosome 3 in head and neck squamous cell carcinoma of Indian patient population. Oral Oncol 2002; 38:6–15.
Tripathi A, Banerjee S, Chunder N, et al. Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients. J Cancer Res Clin Oncol 2003; 129:642–50.
Chunder N, Mandal S, Roy A, Roychoudhury S, Panda CK. Analysis of different deleted regions in chromosome 11 and their interrelations in early and late onset breast tumors: Association with Cyclin D1 and survival. Diagn Mol Pathol 2004; 13:172–182.
Nair MK, Sankaranarayanan R, Nair KS, et al. Overall survival from breast cancer in Kerala, India, in relation to menstrual reproductive and clinical factors. Cancer 1993; 71:1791–6.
Ingvarsson S, Geirsdottir EK, Johannesdottir G, et al. High incidence of loss of heterozygosity in breast tumors from carriers of the BRCA2 999del5 mutation. Cancer Res 1998; 58:4421–5.
Savelyeva L, Claas A, Matzner I, et al. Constitutional genomic instability with inversions, duplications and amplifications in 9p23–24 in BRCA2 mutation carriers. Cancer Res 2001; 61:5179–85.
Mondal G, Tripathi A, Bhattacharya N, et al. Allelic imbalance at chromosome 11 in head and neck squamous cell carcinoma in an Indian patient population. J Clin Pathol 2003; 56:512–8.
Schuuring E. The involvement of chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes. A review. Gene 1995; 159:83–96.
Chen C, Bhalala HV, Qiao H, Dong JT. A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene 2002; 21:6567–72.
Rozenblum E, Vahteristo P, Sandberg T, et al. A genomic map of a 6-Mb region at 13q21-q22 implicated in cancer development: identification and characterization of candidate genes. Hum Genet 2002; 110:111–21.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chunder, N., Mandal, S., Roy, A. et al. Differential Association of BRCA1 and BRCA2 Genes with Some Breast Cancer–Associated Genes in Early and Late Onset Breast Tumors. Ann Surg Oncol 11, 1045–1055 (2004). https://doi.org/10.1245/ASO.2004.02.022
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1245/ASO.2004.02.022